title: Infectious complications of tumor necrosis factor-alpha antagonists.
authors.affiliation: Division of Infectious Diseases and Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
authors.forename: Mohanad
authors.initials: M
authors.lastname: Bakleh
authors.forename: Imad
authors.initials: I
authors.lastname: Tleyjeh
authors.forename: Eric L
authors.initials: EL
authors.lastname: Matteson
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Osmon
authors.forename: Elie F
authors.initials: EF
authors.lastname: Berbari
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D001424:Bacterial Infections / Q000139:chemically induced*; D000068800:Etanercept; D006660:Histoplasmosis / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab; D009894:Opportunistic Infections / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept